Endometrial Cancer | Topics

Pembrolizumab Yields Lasting Anti-Tumor Activity in MSI-H, dMMR Advanced Endometrial Cancer
September 19, 2022

Long-term follow-up from the phase 2 KEYNOTE-158 trial showed enduring anti-tumor activity when pembrolizumab was used to treat patients with microsatellite instability–high/mismatch repair deficient advanced endometrial cancer.

Updated Findings Continue to Support Lenvatinib/Pembrolizumab Combination in Advanced Endometrial Cancer
September 11, 2022

Findings from an updated safety and efficacy analysis of the phase 3 KEYNOTE-775 trial were consistent with the primary analysis and highlighted notable improvements in outcomes among patients with advanced endometrial cancer treated with lenvatinib and pembrolizumab vs physician’s choice.

Avelumab Plus Talazoparib Demonstrates Tolerable Safety Profile in pMMR Endometrial Cancer
September 06, 2022

Results from a phase 2 study highlighted a tolerable safety profile when patients with mismatch repair proficient endometrial cancer were treated with avelumab plus talazoparib.

Avelumab and Talazoparib Demonstrate Promising Safety Profile Recurrent pMMR Endometrial Cancer
August 24, 2022

In a population of patients with recurrent mismatch repair proficient endometrial cancer, treatment with avelumab and talazoparib appeared to be well tolerated.

Pretreatment Neutrophil-to-Lymphocyte Ratio Linked to OS in Endometrial Cancer
August 16, 2022

Findings from a recent study show that a neutrophil-to-lymphocyte ratio of less than 6 before treatment was correlated with improved overall survival for patients with endometrial cancer.

ddPCR Analysis Effective in Identifying POLE Mutations in Endometrial Cancer, Study Finds
July 22, 2022

Investigators recommended that ddPCR testing and immunohistochemical staining be used to detect POLE status and p53/mismatch repair status, respectively, and allow for more rapid classification and risk-stratification.

Investigators Identify 12 Immune-Related lncRNAs That Could Impact Endometrial Cancer Prognosis
July 14, 2022

Several immune-related long noncoding RNA signatures—including PCAT19 and SCARNA9—may be associated with prognosis in patients with endometrial cancer, according to the new research.

Behavioral Weight Loss Program Successful Among Survivors of Endometrial Cancer
June 22, 2022

Endometrial cancer survivors experienced clinically significant weight loss after participating in a behavioral weight loss program.

Dostarlimab Improves Antitumor Activity in Advanced Endometrial Cancer
June 09, 2022

The GARNET trial expansion cohorts showed durable antitumor activity across multiple populations of patients treated with dostarlimab in advanced endometrial cancer.

Selinexor Yields PFS Improvement in Advanced Endometrial Cancer Vs Placebo
June 07, 2022

Patients enrolled on the phase 3 ENGOT-EN5/GOG-3055/SIENDO study with advanced or recurrent endometrial cancer appeared to benefit from treatment with selinexor compared with placebo.